Novo Nordisk will cut US list prices for Ozempic and Wegovy by up to fifty percent next year
Novo Nordisk will reduce US list prices for its popular weight loss drugs by up to half next year. The move follows reports from the Wall Street Journal today.
Insights:
Novo Nordisk A/S announced plans on February 24, 2026, to cut list prices for its diabetes and weight-loss drugs Ozempic and Wegovy in the United States 
US by up to 50% starting next year. This development, which was reported by the Wall Street Journal, directly alters list pricing for major products in the pharmaceutical market. The move is described as large in scale for medications that are widely considered blockbusters.
US by up to 50% starting next year. This development, which was reported by the Wall Street Journal, directly alters list pricing for major products in the pharmaceutical market. The move is described as large in scale for medications that are widely considered blockbusters.The announced plan is scheduled to take effect next year, marking a significant shift in the U.S. market. While the price reductions are focused on American consumers, the company maintains its global operations with roots in Denmark 
DK. This pricing action comes at a time when major pharmaceutical firms, including Eli Lilly and Company , are central to the landscape of diabetes and weight-loss treatments.
DK. This pricing action comes at a time when major pharmaceutical firms, including Eli Lilly and Company , are central to the landscape of diabetes and weight-loss treatments.
